Dose-dependent induction of apoptosis by R-apomorphine in CHO-K1 cell line in culture

Neuropharmacology

Volumn 45, Issue 2, 2003, Pages 182-189

  Pardini, Carla ^a   Vaglini, Francesca ^a   Galimberti, Sara ^a   Corsini, Giovanni U ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Apomorphine; Apoptosis; CHO K1 cell line

Indexed keywords

AGAROSE; ANNEXIN; APOMORPHINE; BIOLOGICAL MARKER; DNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL DEATH; CELL NUCLEUS; CELL PROLIFERATION; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPOSURE; FEMALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL;

EID: 0038168698     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00152-7     Document Type: Article

References (56)

1. Agid Y. Levodopa: is toxicity a myth? Neurology. 50:1998;858-863.
2. Battaglia G., Gesi M., Lenzi P., Buscati C.L., Soldani P., Orzi F., Rampello L., Nicoletti F., Ruggeri S., Fornai F. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity. Ann. NY Acad. Sci. 965:2002;254-256.
3. Blum D., Torch S., Lamberg N., Nissou M.F., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:2001;135-172.
4. Chiarenza A., Scarselli M., Novi F., Lempereur L., Bernardini R., Corsini G.U., Maggio R. Apomorphine, dopamine, and phenylethylamine reduce the proportion of phosphorylated insulin receptor substrate 1. Eur. J. Pharmacol. 433:2001;47-54.
5. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science. 294:2001;1346-1349.
6. Coronas V., Feron F., Hen R., Sicard G., Jourdan F., Moyse E. In vitro induction of apoptosis or differentiation by dopamine in an immortalized olfactory neuronal cell line. J. Neurochem. 69:1997;1870-1881.
7. Corsini G.U., Maggio R., Vaglini F. Molecular and cellular events regulating dopamine neuron survival. Di Chiara G. Handbook of Experimental Pharmacology, vol. 154/II, "Dopamine in the CNS" 2002;321-386 Springer Verlag, Berlin Heidelberg.
8. Dexter D.T., Holley A.E., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased levels of hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9:1994;92-97.
9. Donaldson J., McGregor D., LaBella F. Manganese neurotoxicity: a model for free radical mediated neurodegeneration? Can. J. Physiol. Pharmacol. 60:1982;1398-1405.
10. El Bachà R.S., Daval J.L., Koziel V., Netter P., Minn A. Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants. Biochem. Pharmacol. 66:2001;73-85.
11. Ernst A.M. Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia. 10:1967;316-323.
12. Gassen M., Glinka Y., Pinchasi B., Youdim M.B. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308:1996;219-225.
13. 2 and 6-hydroxydopamine. Mov. Disord. 13:1998;342-438.
14. Gotz M.E., Kunig G., Riederer P., Youdim M.B. Oxidative stress: free radical production in neural degeneration. Pharmacol. Ther. 63:1994;37-122.
15. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
16. Grandas F., Obeso J.A. Motor response following repeated apomorphine administration is reduced in Parkinson's disease. Clin. Neuropharmacol. 12:1989;14-22.
17. Grunblatt E., Mandel S., Maor G., Youdim B.H. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77:2001;146-156.
18. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
19. Halliwell B., Gutteridge J.M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219:1984;1-14.
20. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64:1995;919-924.
21. Hornykiewicz O. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Br. Med. Bull. 29:1973;172-178.
22. Jenner P.G., Brin M.F. Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology. 50:1998;S39-S43.
23. Kaul P.N., Brochmann-Hassen E. Auto-oxidation of apomorphine. J. Pharm. Sci. 50:1961;266-267.
24. Kondo Y., Imai Y., Hoio H., Endo T., Nozoe S. Suppression of tumor cell growth and mitogen response by aporphine alkaloids, dicentrine, glaucine, corydine and apomorphine. J. Pharmacobiodyn. 13:1990;426-431.
25. Lees A.J. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam. Clin. Pharmacol. 7:1993;121-128.
26. Maggio R., Armogida M., Scarselli M., Salvatori F., Longoni B.M., Pardini C., Chiarenza A., Chiacchio S., Vaglini F., Bernardini R., Colzi A., Corsini G.U. Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells. Neurotoxicity Res. 1:2000;1-13.
27. Maker H.S., Weiss C., Silides D.J., Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 36:1981;589-593.
28. McLaughlin B.A., Nelson D., Erecinska M., Chesselet M.F. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by mitochondrial inhibitor. J. Neurochem. 70:1998;2406-2415.
29. Mena M.A., Davila V., Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine/cortical astocyte co-culture. J. Neurochem. 69:1997a;1398-1408.
30. Mena M.A., Khan U., Togasaki D.M., Sulzer D., Epstein C.J., Predborski S. Effects of wild type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J. Neurochem. 69:1997b;21-33.
31. Mena M.A., Pardo B., Casarejos M.J., Fahn S., Garcia de Yebenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov. Disord. 7:1992;23-31.
32. Mytilineou C., Han S.K., Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J. Neurochem. 61:1993;1470-1478.
33. Michel P.P., Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 26:1990;428-435.
34. 2 oxidation of dopamine. J. Med. Chem. 38:1995;917-922.
35. Pardo B., Mena M.A., Casarejos M.J., Paino C.L., De Yebenes J.G. Toxic effects of L-DOPA on mesencephalic cell cultures: protection of antioxidants. Brain Res. 682:1995;133-143.
36. Poewe W., Kleedorf B., Wagner M. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease: long-term follow up in 18 patients. Adv. Neurol. 60:1993;656-659.
37. Porat S., Premkumar A., Simantov R. Dopamine induces phenotypic differentiation or apoptosis in a dose-dependent fashion: involvement of the dopamine transporter and p53. Dev. Neurosci. 23:2001;432-440.
38. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
39. Rosenberg P.A. Catecholamine toxicity in cerebral cortex in dissociated cell culture. J. Neurosci. 8:1988;2887-2894.
40. Rukenstein A., Rydel R.E., Green L.A. Multiple agents rescue PC12 cells from serum free cell death by translation and transcription-independent mechanisms. J. Neurosci. 11:1991;2552-2563.
41. Schrell U.M.H., Fahlbusch R., Adams E.F. Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents: presence of high affinity dopamine-D1 receptors. J. Clin. Endocrinol. Metab. 71:1990;1669-1671.
42. Simantov R., Blinder E., Ratovitski T., Tauber M., Gabbay M., Porat S. Dopamine-induced apoptosis in human neuronal cells: inhibition by nucleic acids antisense to the dopamine transporter. Neuroscience. 74:1996;39-50.
43. Spencer J.P.E., Jenner P., Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. NeuroReport. 6:1995;1480-1484.
44. Stokes A.H., Brown B.G., Lee C.K., Doolittle D.J., Vrana K.E. Tyrosinase enhances the covalent modification of DNA by dopamine. Brain Res. Mol. Brain Res. 42:1996;167-170.
45. Stokes A.H., Hastings T.G., Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55:1999;659-665.
46. Stokes A.H., Lewis D.Y., Lash L.H., Jerome W.G. III, Grant K.W., Aschner M., Vrana K.E. Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis. Brain Res. 858:2000;1-8.
47. Sulzer D. α-synuclein and cytosolic dopamine: stabilizing a bad situation. Nature Med. 7:2001;1280-1282.
48. Ubeda A., Montesinos C., Paya M., Alcaraz M.J. Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic. Biol. Med. 15:1993;159-167.
49. Wang B.H., Lu Z.X., Polya G.M. Inhibition of eukaryote protein kinases by isoquinoline and oxazine alkaloids. Planta Med. 63:1997;494-498.
50. Weinreb, O., Mandel, S., Youdim, M.B.H., 2003. cDNA gene expression profile homology of antioxidants and their anti-apoptotic and pro-apoptotic activities in human neuroblastoma cells. FASEB J., in press.
51. Wick M.M., Byers L., Frei F. L-dopa: selective toxicity for melanoma cells in vitro. Science. 197:1977;468-469.
52. Wijsman J.H., Jonker R.R., Keijzer R. A new method to detect apoptosis in paraffin sections: in situ end labelling of fragmented DNA. J. Histochem. Cytochem. 41:1993;7-12.
53. Wroblesky F., LaDue J.S. Lactic dehydrogenase activity in blood. Proc. Soc. Exp. Biol. Med. 90:1995;210-213.
54. Youdim M.B.H. Iron in the brain: implications for Parkinson's and Alzheimer's disease. Mount Sinai J. Med. 55:1988;97-101.
55. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons: a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci. Lett. 170:1994;136-140.
56. Zou L., Jankovic J., Rowe D.B., Xie W., Appel S.H., Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 64:1999;1275-1285.